MedTrace Logo

Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes

NCT07531108 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2026-04-15

No results posted yet for this study

Summary

This study compared the impacts of empagliflozin-metformin, sitagliptin-metformin, and metformin monotherapy in treatment-naive overweight or obese adults with newly diagnosed type 2 diabetes mellitus in Erbil, Iraq. The study monitored participants for 12 weeks. It determined changes in serum omentin-1, resistin, glycemic markers, and anthropometric measures.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Empagliflozin-Metformin

Oral empagliflozin in combination with metformin at standard approved doses, given for 3 months to adults with type 2 diabetes mellitus.

DRUG

Sitagliptin-Metformin

Oral sitagliptin in combination with metformin at standard approved doses, given for 12 weeks to adults with type 2 diabetes mellitus.

DRUG

Metformin

Oral metformin monotherapy at standard approved doses, given for 3 months to adults with type 2 diabetes mellitus.

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • Sedra Bahjat Ismail, M.Sc. candidate · Clinical pharmacy Department, College of Pharmacy, HMU

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2025-11-27
Completion
2025-11-27

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07531108 on ClinicalTrials.gov